| Catalog No. |
TD-HV625016 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1-kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Phosphatonin, FGF-23, HYPF, FGF23, Fibroblast growth factor 23, Tumor-derived hypophosphatemia-inducing factor |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
Q9GZV9 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
KRN-23,UX-023,CAS:1610833-03-8, KRN23 |
| Background |
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |